12/3
09:05 am
ocs
Oculis (NASDAQ:OCS) is now covered by analysts at Lifesci Capital. They set an "outperform" rating and a $55.00 price target on the stock.
Low
Report
Oculis (NASDAQ:OCS) is now covered by analysts at Lifesci Capital. They set an "outperform" rating and a $55.00 price target on the stock.
11/16
09:36 pm
ocs
Is Oculis Holding (NasdaqGM:OCS) Fairly Valued? A Closer Look After Recent Share Movement [Yahoo! Finance]
Low
Report
Is Oculis Holding (NasdaqGM:OCS) Fairly Valued? A Closer Look After Recent Share Movement [Yahoo! Finance]
11/15
01:42 am
ocs
Low
Report
11/13
12:56 pm
ocs
Oculis (NASDAQ:OCS) had its price target lowered by analysts at Bank of America Corporation from $30.00 to $29.00. They now have a "buy" rating on the stock.
Low
Report
Oculis (NASDAQ:OCS) had its price target lowered by analysts at Bank of America Corporation from $30.00 to $29.00. They now have a "buy" rating on the stock.
11/11
08:09 am
ocs
Oculis (NASDAQ:OCS) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $36.00 price target on the stock.
Low
Report
Oculis (NASDAQ:OCS) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $36.00 price target on the stock.
11/11
08:09 am
ocs
Oculis (NASDAQ:OCS) had its price target raised by analysts at HC Wainwright from $36.00 to $42.00. They now have a "buy" rating on the stock.
Low
Report
Oculis (NASDAQ:OCS) had its price target raised by analysts at HC Wainwright from $36.00 to $42.00. They now have a "buy" rating on the stock.
11/11
08:08 am
ocs
Oculis (NASDAQ:OCS) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $51.00 price target on the stock.
Low
Report
Oculis (NASDAQ:OCS) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $51.00 price target on the stock.
11/10
05:27 pm
ocs
Oculis Holding GAAP EPS of CHF -0.32 [Seeking Alpha]
Low
Report
Oculis Holding GAAP EPS of CHF -0.32 [Seeking Alpha]
11/10
04:41 pm
ocs
Oculis Reports Q3 2025 Financial Results and Provides Company Update [Yahoo! Finance]
Low
Report
Oculis Reports Q3 2025 Financial Results and Provides Company Update [Yahoo! Finance]
11/10
04:05 pm
ocs
Oculis Reports Q3 2025 Financial Results and Provides Company Update
Low
Report
Oculis Reports Q3 2025 Financial Results and Provides Company Update
11/5
04:00 am
ocs
Oculis to Participate in Upcoming November Investor Conferences
Low
Report
Oculis to Participate in Upcoming November Investor Conferences
11/1
08:38 pm
ocs
Oculis Holding (OCS): Is the Premium Price-to-Book Ratio Justified After Recent Share Price Gains? [Yahoo! Finance]
Low
Report
Oculis Holding (OCS): Is the Premium Price-to-Book Ratio Justified After Recent Share Price Gains? [Yahoo! Finance]
10/30
04:30 am
ocs
Oculis Announces Oversubscribed $110 Million Financing to Accelerate Privosegtor Development
Medium
Report
Oculis Announces Oversubscribed $110 Million Financing to Accelerate Privosegtor Development
10/14
04:00 am
ocs
Oculis to Spotlight Transformative Late-Stage Pipeline at Eyecelerator and AAO 2025
Medium
Report
Oculis to Spotlight Transformative Late-Stage Pipeline at Eyecelerator and AAO 2025
10/8
08:09 am
ocs
Oculis (NASDAQ:OCS) had its price target raised by analysts at Chardan Capital from $33.00 to $51.00. They now have a "buy" rating on the stock.
Medium
Report
Oculis (NASDAQ:OCS) had its price target raised by analysts at Chardan Capital from $33.00 to $51.00. They now have a "buy" rating on the stock.
10/7
08:10 am
ocs
Oculis (NASDAQ:OCS) had its price target raised by analysts at HC Wainwright from $33.00 to $36.00. They now have a "buy" rating on the stock.
Low
Report
Oculis (NASDAQ:OCS) had its price target raised by analysts at HC Wainwright from $33.00 to $36.00. They now have a "buy" rating on the stock.
10/6
04:26 am
ocs
Oculis Accelerates Privosegtor into Registrational Trials in Acute Optic Neuritis, Pioneering the Path for a Potential First-in-class Neuroprotective Therapy [Yahoo! Finance]
Medium
Report
Oculis Accelerates Privosegtor into Registrational Trials in Acute Optic Neuritis, Pioneering the Path for a Potential First-in-class Neuroprotective Therapy [Yahoo! Finance]
10/6
04:07 am
ocs
Oculis Accelerates Privosegtor into Registrational Trials in Acute Optic Neuritis, Pioneering the Path for a Potential First-in-class Neuroprotective Therapy
Medium
Report
Oculis Accelerates Privosegtor into Registrational Trials in Acute Optic Neuritis, Pioneering the Path for a Potential First-in-class Neuroprotective Therapy
9/24
07:04 am
ocs
Strength Seen in Oculis Holding AG (OCS): Can Its 6.7% Jump Turn into More Strength? [Yahoo! Finance]
Low
Report
Strength Seen in Oculis Holding AG (OCS): Can Its 6.7% Jump Turn into More Strength? [Yahoo! Finance]
9/22
04:07 am
ocs
Oculis Announces Presentation of Phase 2 ACUITY trial results with Privosegtor in Acute Optic Neuritis at ECTRIMS [Yahoo! Finance]
Medium
Report
Oculis Announces Presentation of Phase 2 ACUITY trial results with Privosegtor in Acute Optic Neuritis at ECTRIMS [Yahoo! Finance]
9/22
04:00 am
ocs
Oculis Announces Presentation of Phase 2 ACUITY trial results with Privosegtor in Acute Optic Neuritis at ECTRIMS
Medium
Report
Oculis Announces Presentation of Phase 2 ACUITY trial results with Privosegtor in Acute Optic Neuritis at ECTRIMS
9/21
03:21 am
ocs
Medium
Report
9/13
01:07 am
ocs
Low
Report